Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18449659 | 0.86 | CYP2C19 (0.33) | CYP2C19 | |
| SCHEMBL29919733 | 0.84 | USP2 (0.30) | — | |
| SCHEMBL7044598 | 0.76 | — | — | |
| SCHEMBL5187701 | 0.72 | — | — | |
| SCHEMBL7298646 | 0.71 | — | — | |
| SCHEMBL3084499 | 0.66 | CYP2C19 (0.39) | CYP2C19 | |
| SCHEMBL20159047 | 0.63 | CHRM2 (0.33) | — | |
| SCHEMBL20141506 | 0.63 | CHRM2 (0.33) | — | |
| SCHEMBL534090 | 0.62 | — | — | |
| SCHEMBL5835900 | 0.62 | MAPT (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3347355-B1 | HETEROTRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-108349961-B | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | 西奈山伊坎医学院 | 2022-02-18 | — | — | CN | disclosed |
| US-10759790-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-09-01 | — | — | US | disclosed |
| US-10450282-B2 | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180251456-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-09-06 | — | — | US | disclosed |
| EP-3347355-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | Icahn School of Medicine at Mount Sinai (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-3331867-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | Icahn School of Medicine at Mount Sinai (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017044569-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017024229-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | ICAHN SCHOOL OF MEDECINE AT MOUNT SINAI (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759790-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | FOXO1, HDAC3, HDAC6 | CYP2C19 4417/4885 |
| US-10450282-B2 | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols | DDT, ODC1, CBR1 | CYP2C19 554/4885 |
| US-20180251456-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | FOXO1, HDAC3, HDAC6 | CYP2C19 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.